T2389

Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

CLK1/2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1/2-IN-3 induces nuclear speckle enlargement, which induces S6K pre-mRNA-selective splicing and subsequent inhibition of cell growth of multiple cancer cell types. cancer cell types cell growth.

CL-55 is a novel inhibitor of T3SS.

CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.

Cloricromen is an inhibitor of platelet aggregation.

Dapagliflozin-D5 is a deuterated form of Dapagliflozin (T2389), a competitive SGLT2 inhibitor.

Dapagliflozin-13C6 (glucitol-13C6) is the 13C labeled compound of Dapagliflozin. Dapagliflozin (T2389) has a CAS number of 461432-26-8. Dapagliflozin (T2389) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.